首页> 外国专利> METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

机译:急性重症结肠炎治疗反应的预测方法

摘要

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.
机译:本发明涉及预测急性严重结肠炎治疗反应的方法。目前,尚无药物反应的生物标志物。本发明提供了对急性重症溃疡性结肠炎的一线和二线治疗反应的第一预测工具。从患者的活组织检查中确定了失调的microRNA的假定的mRNA靶标。鉴定了一种15种结肠微RNA的分类器和5种入院时的生物学值,其预测准确度为96.6%,可将反应者与非反应者区分为类固醇。使用类似的方法,确定了6和4种基于粘膜microRNA的算法,将无反应者分为英夫利昔单抗和环孢菌素。特别地,本发明涉及通过测量选自hp_hsa-mir-3934,hp_hsa-mir-100,hsa-miR-718,hp_hsa-的几种miRNA的表达水平来预测急性严重结肠炎治疗反应的方法。 mir-193b,hsa-miR-3150a-5p,hp_hsa-mir-1260b,hsa-miR-938,hsa-miR-518b和hsa-miR-1468。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号